← Companies|Oncorus (sold)
On

Oncorus (sold)

Cambridge MAFounded 201550 employees
Private CapbiotechAcquiredOncology
Platform: oHSV Synthetic
Market Cap
N/A
All Drugs
3
Clinical Trials
6
Failed / Terminated
1
FDA Approved
1
Drug Pipeline (3 programs)
Drug NameCodePhaseTrialsModalityTargetMOAIndications
MotafutibatinibONC-1480Approved3Cell TherapyKIF18AGLP-1agMesoGBM
TalafotisoranONC-9474NDA/BLA1Gene TherapyPSMAAHRantMigraineOvarian Ca
PeminesiranONC-5204Phase 12ERTTIGITKRASG12CiEpilepsyObesity
Financial Documents
This company has been acquired — see parent company for financial filings.
Catalyst Events (6)
2025-08-02
Peminesiran PDUFA
Obesity
Past
2025-09-05
Peminesiran Interim
Obesity
Past
2026-06-21
Peminesiran Interim
Obesity
Interim
2028-05-19
Motafutibatinib Ph3 Readout
GBM
Ph3 Readout
2030-12-24
Motafutibatinib Ph3 Readout
Meso
Ph3 Readout
2031-02-27
Motafutibatinib Ph3 Readout
Obesity
Ph3 Readout